Mantia, C., Kim, C. G., Ahnert, J. R., Alhalabi, O., Wei, A. Z., Stein, M. N., Johnson, M. L., Garmezy, B., Tewari, A., Devarakonda, S., Tripathi, A., Carneiro, B. A., Park, I., Boni, V., Liu, E., Sachdev, J. C., O'Quigley, M., Neilan, C., Beaupre, D. M., Kim, H. R. (2025). Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps892